p53: link to the past, bridge to the future
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Although the p53 tumor suppressor was identified nearly three decades ago and plays a pivotal role in human cancer, its complexity continues to surprise the research community. Indeed, it was only recently discovered that p53 belongs to a multigene family that also includes p63 and p73 (Kaghad et al. 1997; Schmale and Bamberger 1997). Both p63 and p73 express an array of isoforms as a result of multiple promoter usage and alternative splicing (Yang et al. 1998; Zaika et al. 2002). This complexity within the p53 gene family has, until now, been considered a unique feature of p63 and p73. In this issue, Bourdon et al. (2005) use currently available molecular techniques to revisit the structure of p53, the founding member of this gene family. This work reveals that like the p53-related genes p63 and p73, p53 also makes use of several promoters and undergoes alternative splicing to generate multiple isoforms. Thus, a comparison of p53-related genes reveals strikingly similar traits among family members that produce a plethora of related but functionally diverse proteins that add further complexity to the role of p53-related proteins in development, cancer, and aging
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Enzymatic Amplification of DNA In Vitro: The Polymerase Chain Reaction
Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G., & Erlich, H. (1986) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1986.051.01.032 · Cited by 3,558
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 2×
“…isoforms likely explains the fact that although three different mouse models with enhanced p53 activity have been generated (Garcia-Cao et al. 2002; Tyner et al. 2002; Maier et al. 2004) and these mice are not susceptible to spontaneous tumors (Garcia-Cao et al. 2002; Tyner et al. 2002), only two…”
Backgroundp53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810 · cited 19×
“Identification of a novel p53 transcript that initiates within intron 4 prompted Bourdon et al. (2005) to assay this genomic region for promoter activity.”
BackgroundMethodResultInfluentialModulation of mammalian life span by the short isoform of p53
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586 · cited 2×
“…have been generated (Garcia-Cao et al. 2002; Tyner et al. 2002; Maier et al. 2004) and these mice are not susceptible to spontaneous tumors (Garcia-Cao et al. 2002; Tyner et al. 2002), only two of these models develop concomitant accelerated aging phenotypes (Tyner et al. 2002; Maier et al. 2004).”
Background'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally
García‐Cao, I., García‐Cao, M., Martín‐Caballero, J., Criado, L. M., Klatt, P., Flores, J. M., Weill, J., Blasco, M. A., & Serrano, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf595 · Cited by 529
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Chow, V. T. K., Quek, H. H., & Tock, E. P. C. (1993) · Cancer Letters · doi:10.1016/0304-3835(93)90256-9 · Cited by 59 · cited 3×
“Transcripts similar to those encoding the  isoform of p53 were first described in a human T-cell leukemia line (Chow et al. 1993), and have been characterized more recently in normal human cells and called p53i9 (Fig.”
Background
Cited by
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Immunogenicity of induced pluripotent stem cells
Zhao, T., Zhang, Z.-N., Rong, Z., & Xu, Y. (2011) · Nature · doi:10.1038/nature10135 · Cited by 1,444
Murray-Zmijewski, F., Lane, D. P., & Bourdon, J.-C. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401914 · Cited by 523
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., & Topolcan, O. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.021 · Cited by 506
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report
Duffy, M. J., Sturgeon, C., Lamerz, R., Haglund, C., Holubec, V. L., Klapdor, R., Nicolini, A., Topolcan, O., & Heinemann, V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp332 · Cited by 381
Unbalanced alternative splicing and its significance in cancer
Venables, J. P. (2006) · BioEssays · doi:10.1002/bies.20390 · Cited by 299
p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation
Laurikkala, J., Mikkola, M. L., James, M., Tummers, M., Mills, A. A., & Thesleff, I. (2006) · Development · doi:10.1242/dev.02325 · Cited by 265
Self-citationChen, J., Crutchley, J., Zhang, D., Owzar, K., & Kastan, M. B. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0908 · Cited by 93
“Nine different alternatively spliced p53 mRNA products, generated by internal promoter usage or intron retention, have been reported (13, 14).”
BackgroundReassessing the role of p53 in cancer and ageing from an evolutionary perspective
Aranda-Anzaldo, A., & Dent, M. A. R. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.01.001 · Cited by 36
Susceptibility to metanephric apoptosis in bradykinin B2 receptor null mice via the p53-Bax pathway
Fan, H., Stefkova, J., & El-Dahr, S. S. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00037.2006 · Cited by 13
“p53 is a tumor suppressor which maintains genomic integrity by acting as a sequencespecific transcription factor for cell cycle, apoptosis and DNA repair genes (17, 29, 40).”
Background
Metadata
- Authors
- Mills, A. A.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2005-09-15
- Volume
- 19
- Issue
- 18
- Pages
- 2091-2099
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2145036053
- Cited by
- 81
- References
- 7
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.